WHAT THIS PAPER ADDS The present study investigated quality of life (QoL) at a median of 35 months follow up after bone marrow derived cell therapy for severe limb ischemia. QoL is becoming a more important outcome measure, as amputation rates drop globally. Studies investigating cell therapy in limb ischemia do not usually have long-term follow up results. In the present study, QoL is still increased after almost 3 years, both in the cell treated and placebo arms. The information in the current manuscript is valuable for future trials, since it shows that QoL improvement persists even after long-term follow up, in both the treatment and placebo groups. This also underlines the importance of placebo controlled studies in (cell therapy) trials in limb ischemia.
INTRODUCTION
Severe limb ischemia is an important health care issue with an increasing incidence, and is associated with a poor prognosis for both life and limb, low quality of life (QoL), and high treatment costs. 1, 2 A considerable proportion of these patients will reach a stage where revascularization is not an option, and effective pharmacological therapies for severe limb ischemia are lacking. Hence, major amputation is often inevitable. 3 Therefore, novel treatment options are needed, and regenerative medicine strategies, for instance cell based therapies seem promising. 4 Besides amputation rates or amputation free survival, QoL is increasingly appreciated as an important outcome to evaluate treatment success in severe limb ischemia, and improving QoL has become an important treatment goal in this patient population. 3, 5 Several validated instruments are available to assess health related QoL. One of these is the Medical Outcomes Study Short Form 36 (SF-36) Health Survey, a QoL questionnaire that is widely accepted, validated, and commonly used for the assessment of QoL in various diseases, such as peripheral arterial disease (PAD). 6 Patients with no option severe limb ischemia, participating in the JUVENTAS (reJUVenating ENdothelial progenitor cells via Transcutaneous intra-Arterial Supplementation) trial had worse outcomes in almost every domain of the SF-36 questionnaire than patients with less severe PAD and patients with cardiovascular risk factors only. 1 The results of the JUVENTAS trial showed relatively low amputation and mortality rates in both the bone marrow derived mononuclear cell (BMMNC) and placebo groups, with no significant differences between the groups. 7 The study also reported improved QoL after 6 months compared with baseline in both the BMMNC and the placebo group, without significant differences between the groups. Since there was an improvement in QoL in both groups, the question of whether this may be a result of trial participation itself was raised. The authors have investigated whether this increase in QoL compared with baseline persists in the long-term after finishing the study, when the extra attention and care would be ended. In addition it was assessed whether long-term QoL was influenced by major amputation.
METHODS
The JUVENTAS study was a randomized, placebo controlled, double blind clinical trial that aimed to investigate whether repeated intra-arterial infusion of BMMNCs reduces major amputation rates compared with placebo in a large cohort of no option severe limb ischemia patients. Patients were included from September 2006 through June 2012 if they had severely limiting intermittent claudication or limb ischemia and were not suitable for surgical or endovascular revascularization. A flow chart of the study design is displayed in Fig. 1 .
The study rationale and design have been published previously. 8 QoL was assessed at inclusion and 2 and 6 months follow up in the JUVENTAS trial. The study showed no differences in amputation and mortality rates between the BMMNC and placebo group of the trial, and QoL, rest pain, ankle brachial index (ABI), and transcutaneous oxygen (tcO 2 ) pressure improved in both the BMMNC and placebo group, without differences between them. 7 The main findings of the trial are summarized in Box 1.
Validated Dutch versions of the short form 36 9 and EuroQol 5D-3 level version 10 (EQ5D-3L) questionnaires were sent to all participants of the JUVENTAS study. To assess long-term QoL, the same QoL questionnaires as used during the study were sent to all patients who were still alive 9 months after the last participant completed the 6 month follow up of the trial. At the time of questionnaire completion, patients were still blinded to the assigned treatment. Patients were requested to complete and return the forms; after 2 months a reminder was sent to the nonresponding participants.
Major amputation was defined as amputation through or above the ankle. For the analyses, a difference was made between patients who suffered a major amputation since randomization and patients who suffered any major amputation before or after randomization.
This study was conducted according to the declaration of Helsinki and approved by the institutional review board.
QoL questionnaires
The scores of the eight health dimensions of the SF-36 were calculated, with the norm based scores (NBS) and the physical (PCS) and mental component summary (MCS) scores, as explained previously. 1 The EQ5D-3L consists of five domains, which were combined in one score (the mean tariff score), and the self rated EQ-VAS score. The methods for calculating these scores were also reported previously. 1
Data analysis
Data were analyzed using SPSS for Windows version 22 (SPSS Inc., Chicago, IL, USA). Statistical significance was considered at a double sided p < .05, with a Bonferroni correction to adjust for multiple testing. Missing items were imputed if at least 50% of the items had been completed for that specific health dimension; if patients did not return the questionnaire they were omitted from the analyses. Missing data were imputed using the "multiple imputation" function in SPSS. KolmogoroveSmirnov tests for normality were performed and data with a normal distribution were analyzed using the Student t test, and expressed as mean AE SD, while non-normally distributed data were analyzed using the ManneWhitney U or Wilcoxon rank test, and expressed as medians with interquartile range (IQR). Possible predictors for QoL were previously determined based on clinical relevance and analyzed using a linear regression model. For this regression model, the age of patients was divided into 10 year categories.
RESULTS
The JUVENTAS study included 160 patients with no option severe limb ischemia. The baseline characteristics have been described previously and were not different between the treatment groups. 7 The mean increase in PCS at 6 months compared with baseline was 6.3 (95% CI 4.1e8.4) in the BMMNC group and 6.4 (95% CI 3.9e6.8) in the placebo group. For MCS the mean increase was 3.9 (95% CI 0.0e7.8) and 1.7 (95% CI 2.6e5.9), respectively. Follow up of responding patients varied between 13 and 80 months since inclusion. The median follow up was 35.7 months (interquartile range (IQR) 21.4e50.9 months) and 32.9 months (IQR 21.2e50.6) for the BMMNC and placebo groups, respectively. When the long-term follow up QoL questionnaires were distributed, 126 patients (78.8%) were still alive, and 34 had died (21.2%). Of the 126 patients alive, 109 (86.5%) responded to the questionnaires and were analyzed in this study (55 in BMMNC group, 54 in placebo group), the baseline characteristics of the responding patients are summarized in Table 1 .
Mortality and amputation
Sixteen of 79 patients (20.3%) and 18 of 81 patients (22.2%) in the placebo and BMMNC group had died by the start of this follow up study (p ¼ .67).
Since randomization, 20 out of 79 patients (25.3%) in the placebo group and 21 out of 81 patients (25.9%) in the BMMNC group (p ¼ .93) had suffered a major amputation. Overall the major amputation rates, either before or after randomization, were 31.6% (25 of 79 patients) and 29.6% (24 of 81 patients), respectively (p ¼ .87).
Of the 109 patients responding to the questionnaire, 19 suffered a major amputation since randomization and 27 had suffered any major amputation before or after randomization.
Missing items in QoL questionnaires
In total, 17 patients (placebo 9, BMMNC 8) were contacted but did not return the QoL forms. Seven of them had suffered an amputation during the initial 6 month follow up and 10 of them had suffered an amputation at long-term follow up. The percentage of patients with an amputation since randomization was higher in this non-responding group, than in the group that did respond (p ¼ .001).
Three of the non-responders were lost to follow up because of relocation and unknown address, one did not respond because of severe dementia, and one patient refused to complete the questionnaire because of a major At 6 months' follow up, no significant differences were observed for the primary outcome, i.e. major amputation (19% in BMMNC group vs. 13% in placebo group). The safety outcome (all cause mortality, occurrence of malignancy, or hospitalization due to infection) was not significantly different between the groups (relative risk 1.46, 95% confidence interval 0.63e3.38). Secondary outcomes (quality of life, rest pain, ankle brachial index, and transcutaneous oxygen pressure) improved during follow up, without significant differences between the groups. SF-36 physical component summary increased with 6.3 points (IQR 4.1e8.4) in BMMNC group and 6.4 points (IQR 3.9e8.8) in placebo group. Mental component summary increased with 3.9 points (0.0e7.8) in BMMNC group and 1.7 points (IQR À2.6e5.9) in placebo group.
amputation. The remaining 12 patients did not respond for unknown reasons.
Forty-nine patients (45%) had one or more missing items in their returned questionnaires (23 patients in placebo group, 26 in BMMNC group). The groups of patients with and without missing data showed no significant differences in treatment group, age, gender, BMI, history of major amputation, Fontaine's classification at baseline and at 6 months, and pain free walking distance at baseline and at 6 months. Therefore data were imputed without correction for these factors.
QoL in no option severe limb ischemia patients
Participating no option severe limb ischemia patients demonstrated low scores on every domain of the SF-36. Median NBS were below the general population mean of 50. Low scores were, in particular, observed in the physical domains of the SF-36, as illustrated in Fig. 2 .
BMMNC versus placebo
The QoL scores did not differ between the BMMNC and placebo group at long-term follow up in any of the SF-36 domains, as displayed in Table 2 .
The QoL scores of the EQ5D questionnaire did not differ significantly between the groups, the mean tariff score for the placebo group was 0.63 (SD 0.26) and for the BMMNC group 0.65 (SD 0.23) (p ¼ .30). The median EQ-VAS score was also similar in the placebo (63.50; IQR 55.00e74.00) and BMMNC group (61.00; IQR 57.00e75.00, p ¼ .82). 
QoL at long-term compared with baseline
The mean increases in PCS and MCS compared to baseline were 4.38 (95% CI 1.77e6.98) for the BMMNC and 4.19 (95% CI 1.22e7.16) for the placebo group and 4.10 (95% CI 0.24e7.97) for the BMMNC and 2.54 (95% CI e1.00 to 6.10) for the placebo group, respectively. The PCS and MCS at long-term were not significantly different from 6 months, in both trial arms. Overall, the increase in QoL observed at 6 month follow up is maintained at the longterm follow up. The mean changes in PCS and MCS are displayed in Table 3 .
Patients with and without major amputation
For the 19 responding patients that had an amputation since inclusion, median time between amputation and completion of the questionnaire was 25 months (IQR 20e 43 months). For the 27 responding patients that had a contralateral amputation before or ipsilateral amputation after inclusion, median time between amputation and completion of the questionnaire was 30 months (IQR 20e 54 months). Three of these 27 patients had suffered a bilateral amputation.
When SF-36 scores of patients with and without amputation were compared, there were only statistically Table 4 ). However, these differences were not statistically significant after correction for multiple testing. The EQ5D mean tariff score was not significantly different in patients with and without a major amputation (0.68 [SD 0.23] vs. 0.63 [SD 0.25] respectively, p ¼ .30).
The increase in score for patients after amputation compared to baseline (before amputation) was significant for MCS (p ¼ .04) and showed a trend for PCS (p ¼ .07). The group of patients with a bilateral amputation was too small to detect differences in QoL between unilateral and bilateral amputees.
Predictors of quality of life
Age, sex, history of cerebrovascular accident (CVA), history of diabetes, obesity, and smoking status did not significantly relate to QoL scores in patients with no option severe limb ischemia, measured by the PCS and MCS. The results are summarized in Table 5 . For the domain "general health" of the SF-36 questionnaire, the only significantly contributing factor was age (b ¼ 3.41, 95% CI 0.40e6.43). In this population, higher age seems to contribute to a higher SF-36 general health score. For the domain "bodily pain" the only contributing factor was the presence of diabetes mellitus (b ¼ 7.09, 95% CI 0.39e13.79), which seems to increase the score for this domain. For the remaining six domains of the SF-36 there were no significantly contributing characteristics identified.
DISCUSSION
The present extended analysis of the JUVENTAS trial investigated the long-term QoL of patients with no option severe limb ischemia. The results of this study showed that the increase in QoL observed in the JUVENTAS study at 6 months' follow up persisted at a median of 35 months' follow up. There were no significant differences between the BMMNC and placebo group or between patients with and without a history of a major amputation.
It was hypothesized that the equally improved QoL in the BMMNC and placebo group of the JUVENTAS trial might be related to the effect of trial participation itself. The positive effect of trial participation is previously described as the "Hawthorne effect". Originally, the observed effect was that productivity of workers at the Western Electrical company increased no matter what change in working conditions was introduced and the hypothesis was that this increase in worker productivity was produced by the psychological stimulus of being singled out and made to feel important. This effect has been extrapolated to trial patients and is thought to account for the positive effects of trial participation. 11, 12 It was previously reported that patients who assumed they took an active drug had higher QoL scores than patients who assumed they took placebo. 11, 13, 14 The fact that the increases in QoL compared with baseline remained significant at long-term follow up in most domains of the SF-36 reduces the likelihood that the Hawthorne effect played an important role, since at long-term follow up there were no additional visits or care for participating patients, so that benefit from extra attention is not expected. However, a potential long-term "placebo-effect" cannot be ruled out, since patients were still blinded to treatment allocation at the time that questionnaires for the current study were completed. Investigation of the QoL after unblinding of the participants could be an interesting addition to this analysis. Another possible explanation for the increased long-term QoL is the effect previously referred to as "learning effect", which means that completing a questionnaire repetitively modifies the results because the subject learns how to fill it out. 15 Furthermore, the factor "time" seems to be an important variable; QoL scores may differ over time because of spontaneous evolution or because another aspect related to time, like the season, has changed. 15 The number of patients, especially those in the subgroup with major amputation, was too small to draw definite conclusions; however, QoL in patients with or without a history of major amputation did not differ substantially. Whereas patients without a major amputation score higher in the domain "physical functioning", patients with a history of major amputation have a higher QoL score in the domain "bodily pain". In the remainder of the domains and in the summary scores, both groups have similar results. Notably, the non-responders had higher amputation rates than the responding patients. QoL in responding patients with an amputation did not differ significantly from responding patients that did not suffer an amputation. However, it is possible that the non-responding amputees are specifically those patients with worse QoL, which might lead to overestimation of the QoL in the group of amputees. Other potential reasons for not responding to the questionnaires might also be related to a worse QoL, and hence result in further overestimation of the actual QoL. Furthermore, approximately 45% of the returned questionnaires had one or more missing items, which were imputed and hence might have influenced the results.
The reliability of the summary scores (PCS and MCS) has been subject of debate, mainly because of different results from correlated and uncorrelated component summary scores. 16e19 This could lead to misinterpretation of the results of the SF-36 questionnaires. However, the scores of the eight domains were also analyzed separately, and provided similar results. 20 In conclusion, the improved QoL in no option severe limb ischemia patients that participated in the JUVENTAS trial persisted after finishing the study until a median follow up of 35 months, without any difference between the BMMNC and placebo treated patients. Moreover, the occurrence of a major amputation did not substantially influence QoL.
